Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: The Advocate reports national and local politicians, law enforcement, health care experts and social services professionals attended a summit Tuesday in Baton Rouge hosted by Republican U.S. Sen. Bill Cassidy of Louisiana. They agreed providing mental health services to keep patients out of emergency rooms and jail is vital, but the speakers said it must be a bottom-up effort. Cynthia Kemp says she had worked toward better service in Arlington, Virginia, roughly a decade ago, raising about $800,000 for a jail diversion program and crisis intervention team. She’s now with the federal Substance Abuse and Mental Health Services Administration. Cassidy says communities need to leverage local money to collect federal grant assistance. ___ Information from: The Advocate, http://theadvocate.com Claim: Mental health care summit: Local officials must lead effort.
[A]: Federal officials say Louisiana leaders must take the lead in addressing mental health care for their own communities.


[Q]: Paragraph: The Sackler family owns Purdue Pharma, the privately held drug company that has made billions from OxyContin, and Sacklers hold most of the seats on the board. Members of the family have been accused in a case brought by the state of Massachusetts of deceiving patients and doctors about the drug’s risks as deaths mounted. And documents recently released in the case shine new light on former Purdue Pharma President Richard Sackler’s role in the aggressive marketing of the powerful opioid. As the allegations mount, family members who made their fortunes well before OxyContin even went on the market have sought to distance themselves from their relatives. At the same time, activists have called on institutions to cut ties with the Sacklers, staging protests at museums that have received millions in donations. “The Sackler name is becoming synonymous with the opioid epidemic, and it is damning for these institutions to have their name up,” said Nan Goldin, a photographer whose works have been displayed at Harvard’s Arthur M. Sackler Museum and at New York’s Metropolitan Museum of Art, which has a Sackler Wing. Lost in the outrage: One of the most generous and best known of the Sacklers died in 1987, nearly a decade before OxyContin was released. Arthur M. Sackler made his money from medical research, medical advertising and trade publications. His younger brothers, Raymond and Mortimer, bought out his stake after he died. Arthur Sackler’s name is on a gallery at the Smithsonian, a wing of galleries at London’s Royal Academy of Arts and a museum at Beijing’s Peking University. The Sackler Wing at the Met, which houses the celebrated Temple of Dendur from ancient Egypt, was funded by all three brothers. Richard has likewise donated heavily to various institutions. After a federal investigation, Purdue Pharma and three executives — none of them Sacklers — pleaded guilty in 2007 and agreed to pay more than $600 million for misleading the public about the risks of OxyContin. The Stamford, Connecticut, company has also been hit with a multitude of lawsuits over its role in the opioid crisis that killed more than 47,000 people in 2017 alone. Arthur’s nephew, Richard Sackler, who became president of Purdue Pharma in 1999 and remains on the board, is at the center of the litigation. He and other current and former executives have been accused of hiding the dangers of the drug from doctors and patients, encouraging physicians to prescribe more of the highest doses and minimizing the abuse crisis as it was unfolding. “This is not too bad. It could have been far worse,” he wrote to Purdue Pharma executives in 2001 after a federal prosecutor reported that 59 people in one state had died from OxyContin, according to documents released this week in the Massachusetts case. At the launch party for OxyContin in 1996, Richard Sackler boasted the drug would bring a “blizzard of prescriptions that will bury the competition,” the documents say. Years later, they say, he sought to shift blame onto drug users themselves, recommending the company “hammer on the abusers in every way possible.” “Richard followed that strategy for the rest of his career: collect millions from selling addictive drugs, and blame the terrible consequences on the people who became addicted,” attorneys in Massachusetts Attorney General Maura Healey’s office wrote. “By their misconduct, the Sacklers have hammered Massachusetts families in every way possible. And the stigma they used as a weapon made the crisis worse.” A spokesman for Richard Sackler’s family referred questions about the lawsuit to the company. Purdue Pharma said in a statement that Massachusetts’ case — the first one brought by a state to personally name members of the Sackler family — is “littered with biased and inaccurate characterizations.” The company said it will “aggressively defend against these misleading allegations.” Arthur Sackler’s widow and children insist that they never financially benefited from the sale of OxyContin. “It is a gross injustice to connect Arthur to the opioid crisis some 30 years after his death when he had nothing to do with it,” Dame Jillian Sackler said in a statement. “It denies the many important contributions he made working to improve world health and to build cultural bridges between peoples.” But activists have made no distinction between Arthur and his relatives. In July, dozens of activists led by Goldin held a protest inside the Arthur M. Sackler Museum at Harvard, scattering pill bottles and holding banners that read “SHAME ON SACKLER.” Similar demonstrations have been held at the Met and the Smithsonian. Goldin, who was addicted OxyContin for years, said that getting the institutions to act will be difficult. “Who is going to turn down the money? They offer millions to these institutions, and the board members are not necessarily committed to action, so it’s going to take a lot,” she said. A Met spokesman said that the Sackler family’s support began decades before the opioid crisis, but that the museum will be examining its gift acceptance policies. The Guggenheim, home to the Sackler Center for Arts Education, had no comment. A Harvard spokesman said in an email that Arthur Sackler’s donation in 1982 paid for the construction of the building that originally housed the museum but that his foundation does not fund the museum. ___ Associated Press reporter Verena Dobnik contributed to this report from New York. ___ Follow Alanna Durkin Richer at http://www.twitter.com/aedurkinricher Claim: Opioid crisis brings unwanted attention to wealthy family.
[A]: The Sackler name is emblazoned on the walls at some of the world’s great museums and universities, including the Smithsonian, the Guggenheim and Harvard. But now the family’s ties to OxyContin and the painkiller’s role in the deadly opioid crisis are bringing the Sacklers a new and unwanted kind of attention and complicating their philanthropic legacy.


[Q]: Paragraph: "The story provided cost estimates for angioplasty. It would have been more complete to include comparable information about the costs of medical therapy. The story discussed the comparable outcomes of the two treatments in terms of heart attacks and death. It also explained that at least initially, angioplasty coupled with medical therapy provided relief of angina to more people (8%) than did medical therapy alone but that this difference between the treatments only lasted for 3 years. The story did not provide an explicit list of harms associated with either treatment. It did mention the increased clotting risks associated with one particular type of stent (drug-coated). The story mentioned several studies that compared people with coronary artery disease who were treated with angioplasty and medical therapy with those that received only medical therapy which found no difference in outcomes such as the numbers who had heart attacks. It also provided quantitative information about how the two treatment approaches compared in terms of symptom reduction For the most part, the story did not engage in overt disease mongering. That said, however, the story opened with a disease mongering vignette that involved medical protocols which were not the subject of the story. And describing angina as ""crushing"" and ""debilitating"" makes it seem worse on the average than it really is. However, the balance of the story did not use scare tactics when talking about coronary artery disease, and in using data to tell the story. Several cardiologists were interviewed for this story. The story covered two of the three treatment options for coronary artery disease. It would have been a more complete piece if it had included mention of coronary bypass surgery. The story was about the use of angioplasty (stents) and medical therapy as compared to medical therapy alone as treatment for coronary artery disease. From the discussion, it was clear that both treatments are currently in common use and appear to be widely available. It was clear from that the story was not about a novel form of treatment but rather a recent line of evaluation of two treatment approaches in current practice. It’s clear this story didn’t rely on a news release; it was based on independent analyses." Claim: Angioplasty’s golden era may be fading
[A]:
This was an informative story exploring how medical therapy alone stacks up against medical therapy plus angioplasty as a treatment for coronary artery disease. It highlighted several important issues about medical practice and the treatment of coronary artery disease in particular. While the story never fully described the importance of randomized clinical trials for establishing whether treatment approaches provide the benefit they are thought to convey, it was clear from this story that several recent studies have failed to demonstrate superiority of angioplasty as a treatment for coronary artery disease. The story did mention that angioplasty is a beneficial treatment during a heart attack. The point to be made here is that just because it is an effective way of treating a heart attack does not mean that it is an effective way of preventing a heart attack. Overall, a solid job with independent analyses, context, and data.